Metsera (NASDAQ:MTSR) Issues Quarterly Earnings Results

Metsera (NASDAQ:MTSR) announced its earnings results on Monday. The company reported ($1.03) EPS for the quarter, Zacks reports.

Metsera Trading Down 3.6%

NASDAQ MTSR opened at $23.88 on Monday. Metsera has a 12 month low of $12.30 and a 12 month high of $32.81. The business has a 50-day moving average of $22.80.

Analyst Ratings Changes

A number of brokerages have commented on MTSR. Bank of America assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target for the company. Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating for the company. Guggenheim assumed coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 target price for the company. Finally, Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating on the stock.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.